VandenplasYBelliDCBenatarACadranelSCucchiaraSDupontC, The role of cisapride in the treatment of paediatric gastroesophageal reflux. A medical position statement of the European Society of Paediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr1999; 28: 518–28.
2.
FerrimanA. UK licence for cisapride suspended (editorial). BMJ2000; 321: 259.
3.
VandenplasY. Clinical use of cisapride and its risk–benefit in paediatric patients. Eur J Gastroenterol Hepatol1998; 10: 871–81.
4.
LewinMBBryantRMFenrichALGrifkaRG. Cisapride induced long QT interval. J Pediatr1996; 128: 279–81.
5.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEA, A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–45.
